Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States

Author:

Smith Terry J.12,Cockerham Kimberly345,Lelli Gary6,Choudhary Chitra7,Taylor Stephanie8,Barretto Naina8,Enstone Ashley9,Oliver Louisa9,Lynch Judah9,Holt Robert J.8

Affiliation:

1. Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, Ann Arbor, Michigan

2. Division of Metabolism, Endocrine and Diabetes, Michigan Medicine and University of Michigan, Ann Arbor

3. Stanford Department of Ophthalmology, Palo Alto, California

4. Central Valley Eye Medical Group, Stockton, California

5. Senta Clinic, San Diego, California

6. Weill Cornell Medical Center, New York, New York

7. Kansas University Medical Center, Kansas City

8. Horizon Therapeutics, Deerfield, Illinois

9. Adelphi Values PROVE, Manchester, United Kingdom

Abstract

ImportanceThyroid eye disease (TED) results in varying degrees of proptosis and diplopia negatively affecting quality of life (QoL), producing possibly substantial visual changes, disfigurement, and disability.ObjectiveTo determine the association of varying TED severities with QoL in a non-TED population by assessing health state utility scores.Design, Setting, and ParticipantsThis qualitative study, conducted from April 20, 2020, to April 29, 2021, assessed health states for active, moderate-severe TED, and values were elicited using time trade-off methods. Six health states of varying severity were determined from 2 placebo-controlled clinical trials (171 patients with TED and clinical activity score ≥4, ±diplopia/proptosis) and refined using interviews with US patients with TED (n = 6). Each health state description was validated by interviews with additional TED patient advocates (n = 3) and physician experts (n = 3). Health state descriptions and a QOL questionnaire were piloted and administered to a general population. Visual analog scales (VASs) were also administered to detect concurrence of the findings.Main Outcomes and MeasuresTED health state utility scores and whether they differ from one another were assessed using Shapiro-Wilk, Kruskal-Wallis, pairwise Wilcoxon rank sum, and paired t tests.ResultsA total of 111 participants completed time trade-off interviews. The mean (SD) utility value was 0.44 (0.34). The lowest (worse) mean utility value was observed in the most severe disease state (constant diplopia/large proptosis) with 0.30 (95% CI, 0.24-0.36), followed by constant diplopia/small proptosis (0.34; 95% CI, 0.29-0.40), intermittent or inconstant diplopia/large proptosis (0.43; 95% CI, 0.36-0.49), no diplopia/large proptosis (0.46; 95% CI, 0.40-0.52), and intermittent or inconstant diplopia/small proptosis (0.52; 95% CI, 0.45-0.58). The highest (best) mean value, 0.60 (95% CI, 0.54-0.67), was observed for the least severe disease state (no diplopia/small proptosis).Conclusions and RelevanceThese findings suggest that patients with active, moderate-severe TED may have substantial disutility, with increasing severity of proptosis/diplopia more likely to have detrimental associations with QoL. These health state scores may provide a baseline for determining QoL improvement in these TED health states (utility gains) treated with new therapies.

Publisher

American Medical Association (AMA)

Subject

Ophthalmology

Reference28 articles.

1. Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease.;Lazarus;Best Pract Res Clin Endocrinol Metab,2012

2. Prevalence and associated factors for thyroid eye disease (TED) in the AAO IRIS registry.;Hyman;Invest Ophthalmol Vis Sci,2020

3. Thyroid eye disease: pathogenesis and treatment.;Sikder;Ophthalmologica,2010

4. Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype.;Manji;J Clin Endocrinol Metab,2006

5. Graves’ ophthalmopathy.;Bahn;N Engl J Med,2010

Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3